Skip to content
naulon

No retraction, correction or concern found when last checked on Nov 2, 2026.

Deconstructing GSK‐3: The Fine Regulation of Its Activity

Miguel Medina, Francisco Wandosell

International Journal of Alzheimer’s Disease · 2011 · CC BY

doi:10.4061/2011/479249

Abstract

Glycogen synthase kinase‐3 (GSK‐3) unique position in modulating the function of a diverse series of proteins in combination with its association with a wide variety of human disorders has attracted significant attention to the protein both as a therapeutic target and as a means to understand the molecular basis of these disorders. GSK‐3 is ubiquitously expressed and, unusually, constitutively active in resting, unstimulated cells. In mammals, GSK‐3 α and β are each expressed widely at both the RNA and protein levels although some tissues show preferential levels of some of the two proteins. Neither gene appears to be acutely regulated at the transcriptional level, whereas the proteins are controlled posttranslationally, largely through protein‐protein interactions or by posttranslational regulation. Control of GSK‐3 activity thus occurs by complex mechanisms that are each dependent upon specific signalling pathways. Furthermore, GSK‐3 appears to be a cellular nexus, integrating several signalling systems, including several second messengers and a wide selection of cellular stimulants. This paper will focus on the different ways to control GSK‐3 activity (phosphorylation, protein complex formation, truncation, subcellular localization, etc.), the main signalling pathways involved in its control, and its pathological deregulation.

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.